Drug Detail

Information about Sutent + Stivarga

Links
Trials of this drug
	A Non-randomized, Open-label, Single-center Phase Ib Study of Short Cycles of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Progressing After Prior Therapy With Tyrosine Kinase Inhibitors: SURE Trial

	ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST

Trial results
	CCR- Phase I study of rapid alternation of sunitnib and regorafenib for the treatment of tyrosine-kinase inhibitor refractory GIST

	Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours